dds are that every person in the world knows, loves or is someone confronting cancer. It is the second leading cause of death globally and can change lives in an instant. With its devastating impact on people and families worldwide, bold and immediate action from the global health community is needed to aggressively transform cancer care and change the trajectory of the disease.
At Johnson & Johnson our commitment to innovation has paved the way in oncology for more than 30 years. We work every day to get in front of cancer, convening the brightest minds to create, nurture and deliver new approaches to detect, intercept and one day cure this disease.
Our reach, resources, and network of connections across the Johnson & Johnson Family of Companies, academia, governments and other healthcare organizations are helping address unmet challenges in the deadliest cancers, developing novel and differentiated innovations within pharmaceuticals and medical technologies.
While it’s in our nature to challenge the status quo and strive for the seemingly unattainable, it’s our passion to help patients that drives us. Maintaining health and creating a sense of hope for all people impacted is what propels us to fight this disease at every stage—even before it starts. We will not stop until we have eliminated cancer.
I am inspired by our scientists who bring a relentless, innovative focus every day toward our vision of the elimination of cancer, and by the patients who are counting on us to get there.
I am excited by the disruptive potential of our therapies and by our team’s passion to transform treatment paradigms, advance transformational science, and to deliver upon such progress for patients with cancer.
We are committed to helping break down barriers and reduce health inequities in clinical trial participation among people from racially and ethnically diverse backgrounds, who are critical to our vision of eliminating cancer in all communities.
We must always remember that behind every cancer diagnosis is a person just like you or me. I am deeply committed to bringing new therapies to the patients who need them, with a focus on helping them not only live longer, but live better with cancer.
Together, we are working to change the trajectory for lung cancer patients. Our multidisciplinary approach combines the power of our J&J expertise in Pharmaceuticals and MedTech to develop intratumoral therapies delivered directly to malignant tumors for less invasive, more precise treatment.
Asia ranks first in the world in cancer deaths. As a former physician, I’m constantly touched by the courage and faith patients and their families demonstrate when battling cancer, and I am inspired by the scientists and innovators who are determined to change the trajectory of cancer with transformational treatment solutions.
With our passion to transform the future of medical intervention, our team across Johnson & Johnson MedTech strives to push the boundaries of R&D to make our devices and solutions smarter, less invasive and more personalized for the patients and doctors we serve.
The pandemic shows the importance of being able to prevent, intercept or cure diseases, to eliminate them rather than manage their consequences. At Johnson & Johnson, we are applying these principles to other diseases, including lung cancer. I look forward to a day when people know cancer from history books only.
I am inspired by the work we do at Janssen every day to progress diversity and inclusion in clinical trials and advance health equity, especially for the historically underserved and underrepresented populations disproportionately impacted by cancer.